Changes in ventricular septal thickness in systemic hypertension during treatment with methyldopa and prazosin
| Autor: | Ole M. Pedersen, Magne Følling, Helge Haugland |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class Heart Ventricles Vasodilation Internal medicine medicine Prazosin Heart Septum Humans cardiovascular diseases Methyldopa Labetalol Antihypertensive drug Clinical Trials as Topic biology business.industry Angiotensin-converting enzyme Hydralazine Minoxidil Echocardiography Hypertension Cardiology biology.protein Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | The American journal of cardiology. 58(6) |
| ISSN: | 0002-9149 |
| Popis: | Centrally active antihypertensive drugs such as methyldopa, β-adrenergic blocking drugs, labetalol and angiotensin converting enzyme inhibitors reduce left ventricular (LV) mass, although this property is lacking in drugs acting only on the peripheral α receptors (hydralazine and minoxidil). 1 The effect of prazosin, a peripheral vasodilator and a frequently used antihypertensive drug, has previously not been studied. In a single-blind crossover study, we looked at the effect of this drug on ventricular septal (VS) thickness and posterior LV wall thickness, comparing it with the effect of methyldopa, using echocardiography. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|